Compare ADMA Biologics Inc (ADMA) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vale SA — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Vale SA trades at $14.15 (market cap $62.60B). The key difference: Vale SA is far larger — about 29.4× ADMA Biologics Inc's market cap, and Vale SA pays a 8.57% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | VALE | |
|---|---|---|
Market Cap | $2.13B | $62.60B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $17.82 |
52-Week Low | $7.60 | $9.53 |
Enterprise Value | $2.20B | $79.52B |
Dividend Yield | — | 8.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VALE trades at $14.69, down 2.0% over the past day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. Revenue for 2025 was $38.40 billion with a net income margin of 7.21%, while cash flow from operations remained strong at $8.80 billion. Recent news includes a board governance dispute and a $2.56 billion decarbonization investment plan announced on June 15, 2026 (Reuters).
The outlook is cautious with a consensus analyst price target of $18.30, implying potential upside, but risks include volatile iron ore prices, rising debt-to-asset ratios, and execution challenges. Earnings growth and cost management are key catalysts for stock performance amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
